Introduction and Objective: Effective diabetes management often relies on the use of advanced technologies such as continuous glucose monitoring (CGM) systems and insulin pumps. However, barriers to accessing and utilizing these tools can significantly hinder individuals with type 1 diabetes (T1D). To explore these challenges, we conducted focus groups and structured interviews with a diverse group of participants, including youth and adults with T1D, their parents and partners, and diabetes care providers, educators, and nurses.Methods: Sixty-three participants were interviewed in focus groups categorized as: youth (14-17) with T1D, adults (18-40) with T1D, partners of adults with T1D, and parents of youth with T1D. Structured interviews were conducted with providers and diabetes nurses/educators. Focus groups discussed continuous glucose monitoring (CGM) and insulin pump use, and associated barriers. Transcribed focus group sessions were analyzed for major themes using Dedoose qualitative research software.Results: There were two primary themes that emerged around barriers to diabetes technology use and effective diabetes management. Participants reported significant struggles with accessing diabetes device supplies. The participants often reported that insurance would not cover their sensors being replenished as well as supplies such as insulin pens and pump supplies. These barriers often led to inconsistencies in use and caused the participants to seek alternative methods of getting their supplies such as seeking support from local nonprofits. The next major theme was reluctance to adhere to prescribed insulin regimens due to fear of weight gain, more prevalent among female than male participants.Conclusion: Youth and young adults face financial and social barriers to diabetes technology use, even when supplies are covered by insurance. Social barriers, such as concerns about insulin-related weight gain, require further attention from providers.
K. Valdez: None. R.I. Pereira: None. J.K. Snell-Bergeon: Stock/Shareholder; GlaxoSmithKline plc. H. Gebre: None. E. Rodriguez: None. C.J. Chartier-Logan: None. A. Gerard Gonzalez: None. R.B. Conway: None. C. Geno Rasmussen: Consultant; Sanofi. R. Shoemaker: None.
American Diabetes Association (11-22-ICTSHD-03)
Source link
Leave a Reply